Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

HER2-enriched tumor initiating cell (HTIC) genomic predictor of response following neoadjuvant trastuzumab-based chemotherapy in HER2+ breast cancer


ABSTRACT: We identified a 17-gene Her2-enriched tumor initiating cell (HTIC) signature in MMTV-Her2/Neu mouse mammary TICs. Here, we show that patients with HTICS+ HER2+:ERα− tumors are more likely to achieve a pathologic complete response to trastuzumab-based neoadjuvant chemotherapy compared with HER2+:ER+ tumors. Neoadjuvant study of 50 HER2-positive breast cancer cases treated with trastuzumab-based chemotherapy pre-operatively. Pre-treatment FNA from primary tumors were obtained and RNA extracted and hybridized to Affymetrix microarrays according to manufacturer protocol. Pathologic response was assessed at the end of neoadjuvant treatment.

ORGANISM(S): Homo sapiens

SUBMITTER: Francisco Esteva 

PROVIDER: E-GEOD-37946 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2012-05-12 | GSE37946 | GEO
2016-03-31 | E-GEOD-62327 | biostudies-arrayexpress
2019-05-08 | GSE130787 | GEO
2019-05-08 | GSE130786 | GEO
2021-12-31 | GSE149283 | GEO
2016-03-31 | GSE62327 | GEO
2021-08-24 | GSE181574 | GEO
2015-10-19 | E-GEOD-55348 | biostudies-arrayexpress
2015-10-06 | GSE66305 | GEO
2015-10-06 | GSE66398 | GEO